IGC Pharma Inc (IGC) News

IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two

- Study Achieves Secondary End Point: Demonstrates Clinical Reduction, approaching statistical significance, at Week Two, in Agitation in...

IGC Pharma Adds Advisor in Artificial Intelligence

IGC Pharma, Inc. ("IGC Pharma," "IGC" or the "Company") (NYSE American: IGC) today announces the addition of Pablo Arbelaez, Ph.D., an expert in...

IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock

IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announced a $3 million strategic investment from funds managed by Bradbury...

IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation

- Interim Data: Study Achieves Primary End Point Demonstrating Clinical and Statistically Significant Reductions Compared to Placebo in Agitation...

IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024

IGC Pharma, Inc. (“IGC Pharma”, “IGC”, or the “Company”) (NYSE American: IGC) today announced that Ram Mukunda, CEO, and Claudia Grimaldi, Vice...

IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline

IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) today announced that it has appointed Terry Lierman as an...

Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model

IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American: IGC) today announced the results of preclinical studies investigating...

IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target

IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) announces that Ascendiant Capital Markets LLC (Ascendiant) has...

IGC Pharma Reports Third Quarter Fiscal 2024 Results

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the third fiscal quarter of 2024 ended...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model

- The Company is targeting a Phase 1 trial in 2024 - IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American: IGC) today...

Form 424B5 - Prospectus [Rule 424(b)(5)]

IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’s

Paving the way for a potential Alzheimer’s drug IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American: IGC) provides details on...

IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s Trial

- ClinCloud has dosed its first patient in trial investigating the safety and efficacy of IGC-AD1 on agitation in Alzheimer’s Disease - IGC...

Form EFFECT - Notice of Effectiveness